Screener
Spyre Therapeutics, Inc. SYRE Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Estimated Fair Value |
|---|---|---|---|---|
| Money market funds | $95,448 | — | — | $95,448 |
| Total cash equivalents | $95,448 | — | — | $95,448 |
| Marketable securities: | ||||
| Commercial paper | $164,635 | $1 | $(230) | $164,406 |
| Corporate bonds | 86,788 | 17 | (149) | 86,656 |
| U.S. government treasury securities | 257,224 | 252 | (296) | 257,180 |
| U.S. government agency securities | 136,402 | 20 | (382) | 136,040 |
| Total marketable securities | $645,049 | $290 | $(1,057) | $644,282 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s unrealized gains on investments?
- Spyre Therapeutics, Inc. (SYRE) reported unrealized gains on investments of $290K in Q1 2026.
- How has Spyre Therapeutics, Inc.'s unrealized gains on investments changed year-over-year?
- Spyre Therapeutics, Inc.'s unrealized gains on investments decreased by 64.1% year-over-year, from $807K to $290K.
- What is the long-term trend for Spyre Therapeutics, Inc.'s unrealized gains on investments?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s unrealized gains on investments has grown at a 690.0% compound annual growth rate (CAGR), from $2K to $986K.
Ask your AI about Spyre Therapeutics, Inc.'s unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude